Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
about
An integrated approach to the prediction of chemotherapeutic response in patients with breast cancerTargeting androgen receptor in estrogen receptor-negative breast cancerDistinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcomeAdjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patientsProspective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer.Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapyGenomancy: predicting tumour response to cancer therapy based on the oracle of genetics.Functional analysis of multiple genomic signatures demonstrates that classification algorithms choose phenotype-related genes.Bayesian mixture models for assessment of gene differential behaviour and prediction of pCR through the integration of copy number and gene expression data.Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancerIntegration of biological knowledge and gene expression data for biomarker selection: FN1 as a potential predictor of radiation resistance in head and neck cancer.Mesenchymal/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies.Utility of functional imaging in prediction or assessment of treatment response and prognosis following thermotherapy.Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome.A fuzzy gene expression-based computational approach improves breast cancer prognosticationThe value of FATS expression in predicting sensitivity to radiotherapy in breast cancerImportance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patientsMicroarray analysis of genes associated with cell surface NIS protein levels in breast cancerThe relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer.Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progressionANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2.The macrophage colony-stimulating factor 1 response signature in breast carcinomaClaudin-low breast cancers: clinical, pathological, molecular and prognostic characterizationRandomized adjuvant trials in oncology: a necessity or time-consuming luxury?A Cell-Surface Membrane Protein Signature for Glioblastoma.Kinome expression profiling and prognosis of basal breast cancersMicroarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction.Elevation of SIPL1 (SHARPIN) Increases Breast Cancer RiskStaging of breast cancer in the neoadjuvant setting.A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables.A three-gene model to robustly identify breast cancer molecular subtypesDesign of clinical trials for biomarker research in oncology.A refined molecular taxonomy of breast cancer.Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.Moving from correlative science to predictive oncology.Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patientsPatterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study.p53 amplifies Toll-like receptor 5 response in human primary and cancer cells through interaction with multiple signal transduction pathwaysRelationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer.
P2860
Q21144332-B9F89143-6C58-49BD-8C69-DAB2A14C5B4CQ24312457-69FAFC79-36DE-41E9-A192-968336714DBBQ28273187-FF4A3655-69B0-49C0-89EB-B3D0C2B3FE46Q28477739-737104A8-014B-45B0-952C-0E95CC7CD629Q30433483-76CF74EC-08E2-4964-ABB3-F1C6574D2899Q30434260-42BE3CDA-D978-4795-85A5-01CA028910D4Q30440216-B9467F21-F735-4AF7-B338-31945C56083AQ30496004-4B1A9488-73C6-4C14-91EE-C9983BB1E3EAQ30656573-6436DA3F-A27E-49EE-A8FC-E989464DABEFQ33555064-F1B549AE-70DC-4C65-A8D1-33B126CB0A0CQ33719052-936BFFAF-D510-4066-BAD3-85F60A28994EQ33770298-95CC2C78-E96D-4573-B7D1-6BD69038DEB4Q33790254-DB547DB9-6761-4295-82F9-DCF1E004E3C7Q33813736-DF82E1CF-6CD3-46B3-90FD-C0C422027DA5Q33861620-90403A59-F7B2-46F8-BE89-55C81388CF61Q33888843-C66054F7-6B70-48A2-A357-8FD1D3B2E36CQ33919243-ED28C2FB-23D8-4DE5-A700-42D92DD8E1D9Q34046672-C1B8297E-A7E2-4332-BC18-36BE2C9FF2C0Q34075789-F36ACD35-6116-4949-A8B4-3987F5A04BEEQ34081686-9368BDA0-FA5C-46FC-AB29-3229CB4E1D4CQ34304234-937B0A6B-6F82-4716-8352-14F980495808Q34316094-BC50EE24-5153-4C4A-BEAE-B8AE6C4E8BA7Q34330564-A3EC9204-D146-458D-8138-CBF17EA8A1BCQ34339847-1A16084F-5B57-49F4-B644-9385D28C550FQ34423520-5A6DC6F5-40A6-4B95-9446-29B9259132C7Q34554512-A73C0999-A3C0-4A16-BFA3-6878E2FDE578Q35166659-B045954B-DAA6-4264-8A87-A40CF26E878AQ35558070-90DE7C98-1334-4192-ABB8-33E334CE05B6Q35625533-CD517437-C790-4534-B063-57AB799C6C40Q35638695-94B425B7-81E7-44DA-925C-D95AFD095A81Q35640223-2985B0DF-653D-4294-A12B-5C332E50E26AQ35769036-0AFE6486-79A3-41A8-AF76-E4ED87491F73Q35789708-8F1A0C3A-86A1-4F8D-BD46-BDF1388338EEQ35838290-1BD9261D-76DC-4830-8ED8-9DBB224EEC90Q35889643-812D03A1-11C1-4D8C-BC54-ACA4F0841D72Q36117650-8DA1D908-739D-4A6C-B703-C341E09765D9Q36117673-87939112-596A-47CB-A9ED-86900D52D1E4Q36222126-1C8574CA-2799-438B-A2F8-DC966D445777Q36231932-13B8DFC9-1C54-4086-858D-0A34235F4D71Q36603829-CF403C1B-400D-4121-8D43-12C76B85F4BA
P2860
Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Validation of gene signatures ...... 0994/BIG 00-01 clinical trial.
@ast
Validation of gene signatures ...... 0994/BIG 00-01 clinical trial.
@en
Validation of gene signatures ...... 0994/BIG 00-01 clinical trial.
@nl
type
label
Validation of gene signatures ...... 0994/BIG 00-01 clinical trial.
@ast
Validation of gene signatures ...... 0994/BIG 00-01 clinical trial.
@en
Validation of gene signatures ...... 0994/BIG 00-01 clinical trial.
@nl
prefLabel
Validation of gene signatures ...... 0994/BIG 00-01 clinical trial.
@ast
Validation of gene signatures ...... 0994/BIG 00-01 clinical trial.
@en
Validation of gene signatures ...... 0994/BIG 00-01 clinical trial.
@nl
P2093
P1433
P1476
Validation of gene signatures ...... 0994/BIG 00-01 clinical trial.
@en
P2093
Anil Potti
Chaitanya R Acharya
David Cameron
Emmanuel Blot
Hervé Bonnefoi
Jonas Bergh
Joseph R Nevins
Louis Mauriac
Mario Campone
Mauro Delorenzi
P304
P356
10.1016/S1470-2045(07)70345-5
P577
2007-11-19T00:00:00Z